Consistently with this observation, FasL expression was demonstrated to be higher in CD8+/CD16+/CD56- T-LGLL patients, as compared with other immunophenotypic subgroups [41]. This evidence concerns the gene CD8A and T-cell large granular lymphocyte leukemia.